Delcath shares shoot up on promising trial results

Shares of Delcath Systems shot up 24 percent yesterday evening after the company reported that its anti-cancer technology hit the primary goal of a late-stage trial. The study compared Delcath's PHP system, designed to deliver high doses of chemotherapy directly to the liver, with standard of care. "Delcath could be seen to be becoming one of the few device companies in the U.S. with a multi-hundred million dollar product opportunity, and therefore, we would anticipate a takeover premium to come into the name...," Wedbush Securities analyst Gregory Wade said in a note. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.